These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26371722)

  • 21. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
    Roden DM; Van Driest SL; Wells QS; Mosley JD; Denny JC; Peterson JF
    Circ Res; 2018 Apr; 122(9):1176-1190. PubMed ID: 29700066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects of personalized medicine in cardiovascular diseases.
    Lenfant C
    Metabolism; 2013 Jan; 62 Suppl 1():S6-10. PubMed ID: 22999711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role and impact of SNPs in pharmacogenomics and personalized medicine.
    Laing RE; Hess P; Shen Y; Wang J; Hu SX
    Curr Drug Metab; 2011 Jun; 12(5):460-86. PubMed ID: 21453271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence and resources to implement pharmacogenetic knowledge for precision medicine.
    Caudle KE; Gammal RS; Whirl-Carrillo M; Hoffman JM; Relling MV; Klein TE
    Am J Health Syst Pharm; 2016 Dec; 73(23):1977-1985. PubMed ID: 27864205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian.
    Wu AH; Babic N; Yeo KJ
    Per Med; 2009 May; 6(3):315-327. PubMed ID: 29783510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Pharmacogenomics in Personalized Medicine.
    Singh DB
    Adv Biochem Eng Biotechnol; 2020; 171():369-394. PubMed ID: 31485703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics in the age of personalized medicine.
    Dickmann LJ; Ware JA
    Drug Discov Today Technol; 2016; 21-22():11-16. PubMed ID: 27978982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular drugs and the genetic response.
    Dandona S
    Methodist Debakey Cardiovasc J; 2014; 10(1):13-7. PubMed ID: 24932357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders.
    Edris A; Callier E; Lahousse L
    BMC Med Genomics; 2022 Sep; 15(Suppl 3):193. PubMed ID: 36096833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
    Tan SS; Rutten FF; Hakkaart-van Roijen L
    J Eval Clin Pract; 2011 Dec; 17(6):1094-101. PubMed ID: 21040249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The path to personalized vascular therapy - We are closer than we think.
    Forbes TL
    Vascular; 2016 Oct; 24(5):552-5. PubMed ID: 26767607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
    Borden BA; Galecki P; Wellmann R; Danahey K; Lee SM; Patrick-Miller L; Sorrentino MJ; Nanda R; Koyner JL; Polonsky TS; Stadler WM; Mulcahy C; Kavitt RT; Ratain MJ; Meltzer DO; O'Donnell PH
    Pharmacogenet Genomics; 2019 Feb; 29(2):31-38. PubMed ID: 30531377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indo-Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine.
    Xaviar S; Kumar S; Ramasamy K; Chakradhara Rao US
    Pharmacogenomics; 2021 Jan; 22(2):67-71. PubMed ID: 33305611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions.
    Klein ME; Parvez MM; Shin JG
    J Pharm Sci; 2017 Sep; 106(9):2368-2379. PubMed ID: 28619604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the cost-effectiveness of pharmacogenomics.
    Veenstra DL; Higashi MK; Phillips KA
    AAPS PharmSci; 2000; 2(3):E29. PubMed ID: 11741245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward Personalized Medicine Implementation: Survey of Military Medicine Providers in the Area of Pharmacogenomics.
    DeLuca J; Selig D; Poon L; Livezey J; Oliver T; Barrett J; Turner C; Hellwig L
    Mil Med; 2020 Mar; 185(3-4):336-340. PubMed ID: 31786583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 40. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.